Insulin resistance and psoriasis
- PMID: 38736298
- DOI: 10.1093/bjd/ljae199
Insulin resistance and psoriasis
Conflict of interest statement
Conflicts of interest S.R.F. has received research, speaking and/or consulting support from Eli Lilly and Company, GlaxoSmithKline/Stiefel, AbbVie, Janssen, Alovtech, vTv Therapeutics, Bristol-Myers Squibb, Samsung, Pfizer, Boehringer Ingelheim, Amgen, Dermavant, Arcutis, Novartis, Novan, UCB, Helsinn, Sun Pharma, Almirall, Galderma, LEO Pharma, Mylan, Celgene, Ortho Dermatology, Menlo, Merck & Co, Qurient, Forte, Arena, Biocon, Accordant, Argenx, Sanofi, Regeneron, the National Biological Corporation, Caremark, Teladoc, Eurofins, Informa, UpToDate and the National Psoriasis Foundation. S.R.F. is founder and part owner of Causa Research and holds stock in Sensal Health. S.P.P. declares no conflicts of interest.
Comment on
-
Insulin resistance impairs biologic agent response in moderate-to-severe plaque psoriasis: insights from a prospective cohort study in China.Br J Dermatol. 2024 Sep 18;191(4):616-623. doi: 10.1093/bjd/ljae147. Br J Dermatol. 2024. PMID: 38634691
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
